CapsulesClinical Overview
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with water, with or without food. Because of the prolonged half-life of its active metabolites, steady state is reached after several weeks; changes in dose will not be fully reflected in plasma for 1-2 weeks.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Akathisia, insomnia, weight gain, nausea, headache, dizziness, restlessness. Rare/Severe: Boxed warning: Mortality in elderly dementia patients; neuroleptic malignant syndrome, tardive dyskinesia, and late-onset adverse events due to metabolite accumulation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Boxed warning for elderly patients with dementia-related psychosis. Monitor closely for akathisia and restlessness during dose titration. Because drug and metabolites accumulate over weeks, observe patients for late adverse reactions.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Cariprazine Capsules 3 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Cariprazine Capsules 4.5 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Cariprazine Capsules 6 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.